Dimitri Daldegan-Bueno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dimitri Daldegan-Bueno has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Benedikt Fischer
Faculty of Health Sciences, Simon Fraser University, Vancouver, BC, Canada
9 shared publications - Lucas Oliveira Maia
University of Campinas
9 shared publications - Luís Fernando Tófoli
Laboratory for Interdisciplinary Studies on Psychoactive Substances (LEIPSI) , State University of Campinas, Campinas, Brazil
6 shared publications - Nicholas Hoeh
Department of Psychological Medicine, Faculty of Medical and Health Sciences, University of Auckland, 22 Park Avenue, Grafton, Auckland, 1023, New Zealand
5 shared publications - Suresh Daniel Muthukumaraswamy
University of Auckland
5 shared publications - Anna Forsyth
School of Pharmacy, University of Auckland, Auckland, New Zealand
4 shared publications
Latest Publications
- Open Access
- 25 April 2026
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
Use of identity theories in smoking cessation research: a scoping review
Introduction: The role of identity is increasingly a subject of study in smoking cessation research. However, there is still no standard approach to accounting for the construct of identity in such context. The present review was set to identify theories used in peer-reviewed studies to inform the concept of identity in smoking cessation research. Methods: A systematic search strategy containing MeSH-based terms focusing on identity and smoking cessation was applied to three databases on February 15, 2026. Results: Thirty-one studies were included using qualitative, survey, experimental, mixed-methods, and software-development designs. Nine theories were used: the Plans, Responses, Impulses, Motives, and Evaluations (PRIME) theory of motivation (n = 11); Theory of Planned Behavior (n = 6) and/or Theory of Reasoned Action (n = 1); Social Identity Theory (n = 7) and/or Self-Categorization Theory (n = 2); Social Identity Threat (n = 4); Symbolic Interaction Theory alone (n = 1) or in combination with Integrative Theory of Identity (n = 1); and Cognitive Dissonance Theory (n = 1). These theories served as theoretical frameworks or foundations for developing hypotheses, guiding data collection and analysis, and conceptualizing identity. Despite differences in methods and outcomes, studies highlight that identity plays an important role in smoking cessation. Conclusions: Identified identity theories in smoking cessation research fall broadly into cognitive or social categories, but there is no consistent approach to selecting or operationalizing them. Findings are limited by the number and heterogeneity of studies, but suggest identity is a valuable target for enhancing and developing personalized smoking cessation interventions. Implications: This review explores the theoretical frameworks used to operationalize the construct of identity in smoking cessation research. From more cognitive/individual-focused theories to others that pay further attention to the social aspects of the construct of identity, there is a wide range of theories currently used in smoking cessation research. Despite the heterogeneity of design and results, the construct of identity represents a promising target for cessation interventions and further studies. However, it is essential to address inconsistencies in theoretical approaches, paying attention to the interplay between individual, social, and cultural factors that shape identity and its role in smoking cessation.
- 25 April 2026
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
Open AccessUse of identity theories in smoking cessation research: a scoping review
Introduction: The role of identity is increasingly a subject of study in smoking cessation research. However, there is still no standard approach to accounting for the construct of identity in such context. The present review was set to identify theories used in peer-reviewed studies to inform the concept of identity in smoking cessation research. Methods: A systematic search strategy containing MeSH-based terms focusing on identity and smoking cessation was applied to three databases on February 15, 2026. Results: Thirty-one studies were included using qualitative, survey, experimental, mixed-methods, and software-development designs. Nine theories were used: the Plans, Responses, Impulses, Motives, and Evaluations (PRIME) theory of motivation (n = 11); Theory of Planned Behavior (n = 6) and/or Theory of Reasoned Action (n = 1); Social Identity Theory (n = 7) and/or Self-Categorization Theory (n = 2); Social Identity Threat (n = 4); Symbolic Interaction Theory alone (n = 1) or in combination with Integrative Theory of Identity (n = 1); and Cognitive Dissonance Theory (n = 1). These theories served as theoretical frameworks or foundations for developing hypotheses, guiding data collection and analysis, and conceptualizing identity. Despite differences in methods and outcomes, studies highlight that identity plays an important role in smoking cessation. Conclusions: Identified identity theories in smoking cessation research fall broadly into cognitive or social categories, but there is no consistent approach to selecting or operationalizing them. Findings are limited by the number and heterogeneity of studies, but suggest identity is a valuable target for enhancing and developing personalized smoking cessation interventions. Implications: This review explores the theoretical frameworks used to operationalize the construct of identity in smoking cessation research. From more cognitive/individual-focused theories to others that pay further attention to the social aspects of the construct of identity, there is a wide range of theories currently used in smoking cessation research. Despite the heterogeneity of design and results, the construct of identity represents a promising target for cessation interventions and further studies. However, it is essential to address inconsistencies in theoretical approaches, paying attention to the interplay between individual, social, and cultural factors that shape identity and its role in smoking cessation.
- Open Access
- 18 February 2026
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 145, 111645
LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial
- 18 February 2026
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 145, 111645
Open AccessLSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial
- Open Access
- 4 December 2025
- Published by SAGE Publications in Therapeutic Advances in Psychopharmacology
- Vol. 15
What is it like to microdose LSD for depression? a thematic analysis of participant interviews from an open-label trial
Background: Depressive disorders affect approximately 280 million globally, with many finding treatments ineffective or limited by side effects. Growing evidence suggests that psychedelic therapies may help alleviate depressive symptoms. Among these, lysergic acid diethylamide (LSD) microdosing shows promise for major depressive disorder (MDD). However, research on LSD microdosing in clinical populations remains limited. Objectives: This study aimed to understand the experiences of individuals participating in an open-label trial of LSD microdosing for MDD. Design: Open-label pilot trial in target population (MDD; phase IIa). Methods: Seventeen participants with MDD completed an 8-week LSD microdosing regimen, dosing twice weekly. Following the intervention, participants underwent semi-structured interviews regarding their experiences. Data were analysed using thematic analysis. Results: Themes were grouped into five categories: enhanced self-determination, increased connectedness, improved cognitive processing, better emotional well-being, and negative effects. Conclusion: Reported effects appeared to reinforce one another; that is, self-determination led to feeling more connected, which enhanced cognitive processing and ultimately improved emotional well-being and reduced depressive symptoms. However, this effect was not universal; some individuals reported negative effects or no significant improvement from microdosing LSD. This variability may be due to individual differences in response, insufficient dosage, or the treatment’s lack of effectiveness for some individuals. The presence of side effects highlights the need for a careful titration protocol, while the lack of symptom improvement in some cases reinforces that microdosing is not a guaranteed solution, and expectations should remain realistic. The absence of a placebo control represents a key limitation as it precludes attribution of observed changes specifically to LSD. Trial registration: ANZCTR, ACTRN12623000486628. Registered on 12 May 2023 ( https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=385758 ).
- 4 December 2025
- Published by SAGE Publications in Therapeutic Advances in Psychopharmacology
- Vol. 15
Open AccessWhat is it like to microdose LSD for depression? a thematic analysis of participant interviews from an open-label trial
Background: Depressive disorders affect approximately 280 million globally, with many finding treatments ineffective or limited by side effects. Growing evidence suggests that psychedelic therapies may help alleviate depressive symptoms. Among these, lysergic acid diethylamide (LSD) microdosing shows promise for major depressive disorder (MDD). However, research on LSD microdosing in clinical populations remains limited. Objectives: This study aimed to understand the experiences of individuals participating in an open-label trial of LSD microdosing for MDD. Design: Open-label pilot trial in target population (MDD; phase IIa). Methods: Seventeen participants with MDD completed an 8-week LSD microdosing regimen, dosing twice weekly. Following the intervention, participants underwent semi-structured interviews regarding their experiences. Data were analysed using thematic analysis. Results: Themes were grouped into five categories: enhanced self-determination, increased connectedness, improved cognitive processing, better emotional well-being, and negative effects. Conclusion: Reported effects appeared to reinforce one another; that is, self-determination led to feeling more connected, which enhanced cognitive processing and ultimately improved emotional well-being and reduced depressive symptoms. However, this effect was not universal; some individuals reported negative effects or no significant improvement from microdosing LSD. This variability may be due to individual differences in response, insufficient dosage, or the treatment’s lack of effectiveness for some individuals. The presence of side effects highlights the need for a careful titration protocol, while the lack of symptom improvement in some cases reinforces that microdosing is not a guaranteed solution, and expectations should remain realistic. The absence of a placebo control represents a key limitation as it precludes attribution of observed changes specifically to LSD. Trial registration: ANZCTR, ACTRN12623000486628. Registered on 12 May 2023 ( https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=385758 ).
- Open Access
- 5 November 2025
- Published by Elsevier in Neuropharmacology
- Vol. 283, 110762
LSD microdosing in major depressive disorder: results from an open-label trial
- 5 November 2025
- Published by Elsevier in Neuropharmacology
- Vol. 283, 110762
Open AccessLSD microdosing in major depressive disorder: results from an open-label trial
- Open Access
- 30 August 2025
- Published by Elsevier in Neuropharmacology
- Vol. 280, 110670
Qualitative content analysis of expectations in participants with depression about to begin LSD microdosing treatment: Identifying the need for psychedelic expectancy measures
- 30 August 2025
- Published by Elsevier in Neuropharmacology
- Vol. 280, 110670
Open AccessQualitative content analysis of expectations in participants with depression about to begin LSD microdosing treatment: Identifying the need for psychedelic expectancy measures
- 28 June 2025
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 39 (9) , 990-1006
OAV and 5D-ASC for Brazilian Portuguese: A validation and adaptation study
Background: This study aimed to validate and culturally adapt the Altered States of Consciousness Rating Scale (OAV) and Five Dimensional—Altered States of Consciousness Questionnaire (5D-ASC) for Brazilian Portuguese to measure altered states of consciousness in the context of psychedelic research. Methods: A parallel back-translation model was employed with expert reviews to ensure linguistic and cultural accuracy. The finalized version was pre-tested with 10 participants and subsequently included in an online survey. This survey was completed by 3762 respondents recounting their psychedelic experiences. Exploratory factor analysis and confirmatory factor analysis were conducted to identify the factor structure and validate the scales. Internal consistency and convergent validity were assessed through correlation with the Mystical Experience Questionnaire (MEQ) and Ego Dissolution Inventory (EDI). Results: The analyses confirmed an 11-factor structure for the OAV and a 6-factor structure for the 5D-ASC, both exhibiting strong internal consistency (α > 0.76). Significant correlations were observed between OAV and 5D-ASC factors and the MEQ and EDI, indicating solid convergent validity. Differences in factor scores were noted depending on the substance, setting, and meditation frequency, with higher oceanic boundlessness and anxious ego-dissolution scores for ayahuasca and dimethyltryptamine experiences. Conclusions: The validated scales demonstrated reliable psychometric properties for the Brazilian context. The results highlight cultural aspects influencing subjective experiences with psychedelics. Limitations include sample homogeneity and potential recall bias. Future research should involve more diverse samples to confirm and extend these findings.
- 28 June 2025
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 39 (9) , 990-1006
OAV and 5D-ASC for Brazilian Portuguese: A validation and adaptation study
Background: This study aimed to validate and culturally adapt the Altered States of Consciousness Rating Scale (OAV) and Five Dimensional—Altered States of Consciousness Questionnaire (5D-ASC) for Brazilian Portuguese to measure altered states of consciousness in the context of psychedelic research. Methods: A parallel back-translation model was employed with expert reviews to ensure linguistic and cultural accuracy. The finalized version was pre-tested with 10 participants and subsequently included in an online survey. This survey was completed by 3762 respondents recounting their psychedelic experiences. Exploratory factor analysis and confirmatory factor analysis were conducted to identify the factor structure and validate the scales. Internal consistency and convergent validity were assessed through correlation with the Mystical Experience Questionnaire (MEQ) and Ego Dissolution Inventory (EDI). Results: The analyses confirmed an 11-factor structure for the OAV and a 6-factor structure for the 5D-ASC, both exhibiting strong internal consistency (α > 0.76). Significant correlations were observed between OAV and 5D-ASC factors and the MEQ and EDI, indicating solid convergent validity. Differences in factor scores were noted depending on the substance, setting, and meditation frequency, with higher oceanic boundlessness and anxious ego-dissolution scores for ayahuasca and dimethyltryptamine experiences. Conclusions: The validated scales demonstrated reliable psychometric properties for the Brazilian context. The results highlight cultural aspects influencing subjective experiences with psychedelics. Limitations include sample homogeneity and potential recall bias. Future research should involve more diverse samples to confirm and extend these findings.
- Open Access
- 24 August 2024
- Published by Springer Nature in Trials
- Vol. 25 (1) , 1-13
LSDDEP2: study protocol for a randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups trial of LSD microdosing in patients with major depressive disorder
Background: Major depressive disorder (MDD) poses a significant global health burden with available treatments limited by inconsistent efficacy and notable side effects. Classic psychedelics, including lysergic acid diethylamide (LSD), have garnered attention for their potential in treating psychiatric disorders. Microdosing, the repeated consumption of sub-hallucinogenic doses of psychedelics, has emerged as a self-treatment approach for depression within lay communities. Building upon preliminary evidence and the successful completion of an open-label pilot trial of microdosing LSD for depression (LSDDEP1), this protocol outlines a phase 2b randomised controlled trial (LSDDEP2). The main objective of LSDDEP2 is to assess the modification of depressive symptoms, measured by the Montgomery–Åsberg Depression Rating Scale (MADRS), following a regimen of LSD microdoses versus placebo. Methods: This is a randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups trial of LSD microdosing in patients meeting DSM-5 criteria for major depressive disorder. Participants will undergo an 8-week LSD microdosing regimen using the titratable MB-22001 formulation taking two doses a week. All doses will be self-administered at home and will be titratable from 4 to 20 μg based on subjective perception and tolerability. In addition to depression symptoms, outcome will include psychiatric and personality inventories, sleep and activity tracking, electroencephalography (EEG), blood biomarkers, semi-structured interviews, and safety (e.g. adverse event, laboratory exam) measures. Discussion: This study will be the first randomised controlled trial to administer controlled microdoses of LSD for treatment of MDD in participants’ naturalistic environment. The measures included are designed to assess the drug’s safety, mechanism, and treatment efficacy over placebo in this population. The results of this study will be important for assessing the viability of psychedelic microdosing as an additional treatment option and for informing the direction of future clinical trials. Trial registration: ANZCTR, ACTRN12624000128594. Prospectively Registered on 13 February 2024.
- 24 August 2024
- Published by Springer Nature in Trials
- Vol. 25 (1) , 1-13
Open AccessLSDDEP2: study protocol for a randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups trial of LSD microdosing in patients with major depressive disorder
Background: Major depressive disorder (MDD) poses a significant global health burden with available treatments limited by inconsistent efficacy and notable side effects. Classic psychedelics, including lysergic acid diethylamide (LSD), have garnered attention for their potential in treating psychiatric disorders. Microdosing, the repeated consumption of sub-hallucinogenic doses of psychedelics, has emerged as a self-treatment approach for depression within lay communities. Building upon preliminary evidence and the successful completion of an open-label pilot trial of microdosing LSD for depression (LSDDEP1), this protocol outlines a phase 2b randomised controlled trial (LSDDEP2). The main objective of LSDDEP2 is to assess the modification of depressive symptoms, measured by the Montgomery–Åsberg Depression Rating Scale (MADRS), following a regimen of LSD microdoses versus placebo. Methods: This is a randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups trial of LSD microdosing in patients meeting DSM-5 criteria for major depressive disorder. Participants will undergo an 8-week LSD microdosing regimen using the titratable MB-22001 formulation taking two doses a week. All doses will be self-administered at home and will be titratable from 4 to 20 μg based on subjective perception and tolerability. In addition to depression symptoms, outcome will include psychiatric and personality inventories, sleep and activity tracking, electroencephalography (EEG), blood biomarkers, semi-structured interviews, and safety (e.g. adverse event, laboratory exam) measures. Discussion: This study will be the first randomised controlled trial to administer controlled microdoses of LSD for treatment of MDD in participants’ naturalistic environment. The measures included are designed to assess the drug’s safety, mechanism, and treatment efficacy over placebo in this population. The results of this study will be important for assessing the viability of psychedelic microdosing as an additional treatment option and for informing the direction of future clinical trials. Trial registration: ANZCTR, ACTRN12624000128594. Prospectively Registered on 13 February 2024.
- 18 November 2023
- Published by Elsevier in Aggression and Violent Behavior
- Vol. 74
The association between cocaine product use and violence outcomes in Brazil: A comprehensive, systematized review
- 18 November 2023
- Published by Elsevier in Aggression and Violent Behavior
- Vol. 74
The association between cocaine product use and violence outcomes in Brazil: A comprehensive, systematized review
- 19 January 2023
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 68, 89-104
LSD and language: Decreased structural connectivity, increased semantic similarity, changed vocabulary in healthy individuals
- 19 January 2023
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 68, 89-104
LSD and language: Decreased structural connectivity, increased semantic similarity, changed vocabulary in healthy individuals
- 28 November 2022
- Published by Wiley in Drug and Alcohol Review
- Vol. 42 (2) , 318-336
Cannabis use, risk behaviours and harms in Brazil: A comprehensive review of available data indicators
Issues: Cannabis use and related health/social outcome indicator data for Brazil—where non‐medical cannabis is generally illegal—are limited.Approach: Towards a comprehensive overview of relevant indicators, we searched primary databases by combining MeSH‐index terms related to cannabis, geographic location and subtopic terms (e.g., use, health, mortality) focusing on cannabis use and key outcome indicators in Brazil since 2010. In addition, relevant ‘grey literature’ (e.g., survey reports) was identified. Key indicator data were mainly narratively summarised.Key Findings: Overall, cannabis use has increased somewhat since pre‐2010, with (past‐year) use rates measured at 2–3% for general population adults, yet 5% or higher among youth and/or (e.g., post‐secondary) student populations. For key risk behaviours, the presence of tetrahydrocannabinol‐positivity among motor‐vehicle drivers has been measured at <2%. While the prevalence of cannabis use disorder appears to have decreased, the relative proportion of treatment provided for cannabis‐related problems increased. National‐ and local‐based studies indicated an association of cannabis use with mental health harms, including depression and suicidality. Although some non‐representative and/or local studies contain information, other monitoring data, including cannabis‐related risks and harms (e.g., cannabis‐related driving, mortality, hospitalisations), are limited in availability.Implications and Conclusion: The prevalence of cannabis use in Brazil is comparably low (e.g., relative to elsewhere in the Americas). Data on numerous key cannabis‐related indicators is absent, or limited in scope for Brazil. Considering ongoing evolutions in cannabis control and its status as the most common illicit drug, more comprehensive surveillance of cannabis use and related outcomes is advised.
- 28 November 2022
- Published by Wiley in Drug and Alcohol Review
- Vol. 42 (2) , 318-336
Cannabis use, risk behaviours and harms in Brazil: A comprehensive review of available data indicators
Issues: Cannabis use and related health/social outcome indicator data for Brazil—where non‐medical cannabis is generally illegal—are limited.Approach: Towards a comprehensive overview of relevant indicators, we searched primary databases by combining MeSH‐index terms related to cannabis, geographic location and subtopic terms (e.g., use, health, mortality) focusing on cannabis use and key outcome indicators in Brazil since 2010. In addition, relevant ‘grey literature’ (e.g., survey reports) was identified. Key indicator data were mainly narratively summarised.Key Findings: Overall, cannabis use has increased somewhat since pre‐2010, with (past‐year) use rates measured at 2–3% for general population adults, yet 5% or higher among youth and/or (e.g., post‐secondary) student populations. For key risk behaviours, the presence of tetrahydrocannabinol‐positivity among motor‐vehicle drivers has been measured at <2%. While the prevalence of cannabis use disorder appears to have decreased, the relative proportion of treatment provided for cannabis‐related problems increased. National‐ and local‐based studies indicated an association of cannabis use with mental health harms, including depression and suicidality. Although some non‐representative and/or local studies contain information, other monitoring data, including cannabis‐related risks and harms (e.g., cannabis‐related driving, mortality, hospitalisations), are limited in availability.Implications and Conclusion: The prevalence of cannabis use in Brazil is comparably low (e.g., relative to elsewhere in the Americas). Data on numerous key cannabis‐related indicators is absent, or limited in scope for Brazil. Considering ongoing evolutions in cannabis control and its status as the most common illicit drug, more comprehensive surveillance of cannabis use and related outcomes is advised.